Table Info

Table 1.

A summary of AS1411-functionalized chemotherapeutic drug delivery nanosystems for targeted cancer therapy

Delivery system	Components	Drug(s)	Animal models or/and cells lines	Investigated cancer type	*In vivo/in vitro*	Reference
NP	PLGA-Lecithin-PEG	PTX	MCF-7, GI-1	Breast cancer and gliosarcoma	In vitro	[59]
NP	MF-NR-PLGA	PTX	MCF-7	Breast cancer	In vitro	[60]
NP	PEG-PCL	Docetaxel	BALB/c mice & BALB/c nude mice/C6, bEnd.3	Glioma	In vivo/in vitro	[61]
NP	PLGA-PEG-COOH	PTX	C6 glioma xenograft mice, intracranial C6 glioma rats	Glioma	In vivo	[62]
NP	pPEGMA-PCL-pPEGMA	DOX	MCF-7, PANC-1	Epithelial cancer	In vitro	[63]
NP	HSA	PTX	MCF-7	Breast cancer	In vitro	[64]
NP	PLGA-PEG	Vinorelbine	MDA-MB-231	Breast cancer	In vitro	[65]
NP	Cytochrome C capped mesoporous silica NPs	DOX	Athymic BALB/c nude mice/HepG2	Hepatocellular carcinoma	In vivo/in vitro	[66]
Nanosphere	Colloidal gold nanospheres	-	Fox1^nu nude mice/MCF-7 & MDA-MB-231	Breast cancer	In vivo/in vitro	[67]
Nanostar	Gold nanostar	-	Nude mice, Sprague-Dawley (SD) rats/HT-1080, MDA-MB-231	Fibrosarcoma, breast cancer	In vivo/in vitro	[68]
Drug-DNA adduct	-	DOX	NOD.Cg-Prkdc^SCID IL2 mice/Huh7	Hepatocellular carcinoma	In vivo/in vitro	[69]
Nanotube	SWCNT	DOX	BALB/c nude mice/PC3	Prostate cancer	In vivo/in vitro	[70]
Micelles	Pluronic F127, β-CD-PELA	DOX	BALB/c nude mice/MCF-7	Breast cancer	In vivo/in vitro	[47]
Micelles	TPGS-b-PBAE	PTX	BALB/c nude mice/SKOV3	Ovarian cancer	In vivo/in vitro	[52]
Capsule	Cell membrane capsules	DOX hydrochloride	BALB/c nude mice/QGY-7703	Liver cancer	In vivo/in vitro	[71]
Micelles	PEG-PAE	DOX	MCF-7	Breast cancer	In vitro	[53]

MF: magnetic fluorescence; NR: Nile red; PCL: polycaprolactone; pPEGMA: poly(polyethylene glycol methacrylate); SWCNT: single walled carbon nanotubes; PBAE: blockpoly-(β-amino ester)

Declarations

Author contributions

Pooria SK: Conceptualization, Investigation, Writing-original draft, Writing-review & editing. Pouya SK: Conceptualization, Investigation, Writing-original draft, Writing-review & editing. MTM: Validation, Writing-review & editing, Supervision. All authors contributed to manuscript revision, read, and approved the submitted version.

Conflicts of interest

MTM is an inventor on the issued patents related to AS1411 and the technology discussed in this manuscript has been licensed to the company Qualigen Inc. The other authors declare they have no conflict of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

MTM is supported by NIH Grant 5T32HL134664-3. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Srivastava M, Pollard HB. Molecular dissection of nucleolin’s role in growth and cell proliferation: new insights. FASEB J. 1999;13:1911–22. [DOI]

Tajrishi MM, Tuteja R, Tuteja N. Nucleolin: the most abundant multifunctional phosphoprotein of nucleolus. Commun Integr Biol. 2011;4:267–75. [DOI] [PubMed] [PMC]

Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Cancer Ther. 2006;5: 2957–62. [DOI] [PubMed]

Berger CM, Gaume X, Bouvet P. The roles of nucleolin subcellular localization in cancer. Biochimie. 2015;113:78–85. [DOI]

Guo X, Xiong L, Yu L, Li R, Wang Z, Ren B, et al. Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy. Diagn Pathol. 2014;9:175. [DOI] [PubMed] [PMC]

Fujiki H, Watanabe T, Suganuma M. Cell-surface nucleolin acts as a central mediator for carcinogenic, anti-carcinogenic, and disease-related ligands. J Cancer Res Clin Oncol. 2014;140:689–99. [DOI]

Nisole S, Said EA, Mische C, Prevost MC, Krust B, Bouvet P, et al. The anti-HIV pentameric pseudopeptide HB-19 binds the C-terminal end of nucleolin and prevents anchorage of virus particles in the plasma membrane of target cells. J Biol Chem. 2002;277:20877–86. [DOI]

Abdelmohsen K, Gorospe M. RNA-binding protein nucleolin in disease. RNA Biol. 2012;9:799–808. [DOI] [PubMed] [PMC]

Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, et al. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med. 2013;210:951–68. [DOI]

10.

Huang Y, Shi H, Zhou H, Song X, Yuan S, Luo Y. The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood. 2006;107:3564–71. [DOI]

11.

Mi Y, Thomas SD, Xu X, Casson LK, Miller DM, Bates PJ. Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin. J Biol Chem. 2003;278:8572–9. [DOI]

12.

Sengupta TK, Bandyopadhyay S, Fernandes DJ, Spicer EK. Identification of nucleolin as an AU-rich element binding protein involved in bcl-2 mRNA stabilization. J Biol Chem. 2004;279:10855–63. [DOI]

13.

Otake Y, Sengupta TK, Bandyopadhyay S, Spicer EK, Fernandes DJ. Retinoid-induced apoptosis in HL-60 cells is associated with nucleolin down-regulation and destabilization of Bcl-2 mRNA. Mol Pharmacol. 2005;67:319–26. [DOI]

14.

Hirano K, Miki Y, Hirai Y, Sato R, Itoh T, Hayashi A, et al. A multifunctional shuttling protein nucleolin is a macrophage receptor for apoptotic cells. J Biol Chem. 2005;280:39284–93. [DOI]

15.

Ginisty H, Sicard H, Roger B, Bouvet P. Structure and functions of nucleolin. J Cell Sci. 1999;112:761–72. [DOI]

16.

Abdelmohsen K, Tominaga K, Lee EK, Srikantan S, Kang MJ, Kim MM, et al. Enhanced translation by Nucleolin via G-rich elements in coding and non-coding regions of target mRNAs. Nucleic Acids Res. 2011;39:8513–30. [DOI]

17.

González V, Hurley LH. The C-terminus of nucleolin promotes the formation of the c-MYC G-quadruplex and inhibits c-MYC promoter activity. Biochemistry. 2010;49:9706–14. [DOI]

18.

Pickering BF, Yu D, Van Dyke MW. Nucleolin protein interacts with microprocessor complex to affect biogenesis of microRNAs 15a and 16. J Biol Chem. 2011;286:44095–103. [DOI]

19.

Peter M, Nakagawa J, Dorée M, Labbé JC, Nigg EA. Identification of major nucleolar proteins as candidate mitotic substrates of cdc2 kinase. Cell. 1990;60:791–801. [DOI]

20.

Zhou G, Seibenhener ML, Wooten MW. Nucleolin is a protein kinase C-zeta substrate. Connection between cell surface signaling and nucleus in PC12 cells. J Biol Chem. 1997;272:31130–7. [DOI]

21.

Belenguer P, Caizergues-Ferrer M, Labbé JC, Dorée M, Amalric F. Mitosis-specific phosphorylation of nucleolin by p34cdc2 protein kinase. Mol Cell Biol. 1990;10:3607–18. [DOI]

22.

Zhang D, Liang Y, Xie Q, Gao G, Wei J, Huang H, et al. A novel post-translational modification of nucleolin, SUMOylation at Lys-294, mediates arsenite-induced cell death by regulating gadd45α mRNA stability. J Biol Chem. 2015;290:4784–800. [DOI]

23.

Hovanessian AG, Puvion-Dutilleul F, Nisole S, Svab J, Perret E, Deng JS, et al. The cell-surface-expressed nucleolin is associated with the actin cytoskeleton. Exp Cell Res. 2000;261:312–28. [DOI]

24.

Romano S, Fonseca N, Simões S, Gonçalves J, Moreira JN. Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands. Drug Discov Today. 2019;24:1985–2001. [DOI]

25.

Zhang Y, Lai BS, Juhas M. Recent advances in aptamer discovery and applications. Molecules. 2019;24:941. [DOI]

26.

Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol. 2010;50:237–57. [DOI]

27.

Cibiel A, Pestourie C, Ducongé F. In vivo uses of aptamers selected against cell surface biomarkers for therapy and molecular imaging. Biochimie. 2012;94:1595–606. [DOI] [PubMed]

28.

Yang L, Zhang X, Ye M, Jiang J, Yang R, Fu T, et al. Aptamer-conjugated nanomaterials and their applications. Adv Drug Deliv Rev. 2011;63:1361–70. [DOI]

29.

Zhang Y, Lai BS, Juhas M. Recent advances in aptamer discovery and applications. Molecules. 2019;24:941. [DOI]

30.

Hermann T, Patel DJ. Adaptive recognition by nucleic acid aptamers. Science. 2000;287:820–5. [DOI] [PubMed]

31.

Nakamura Y, Ishiguro A, Miyakawa S. RNA plasticity and selectivity applicable to therapeutics and novel biosensor development. Genes Cells. 2012;17:344–64. [DOI]

32.

Lakhin A, Tarantul V, Gening L. Aptamers: problems, solutions and prospects. Acta Naturae. 2013;5:34–43. [PubMed] [PMC]

33.

Mi P, Cabral H, Kataoka K. Ligand-installed nanocarriers toward precision therapy. Adv Mater. 2020;32:1902604. [DOI]

34.

Elskens JP, Elskens JM, Madder A. Chemical modification of aptamers for increased binding affinity in diagnostic applications: current status and future prospects. Int J Mol Sci. 2020;21:4522. [DOI]

35.

Adachi T, Nakamura Y. Aptamers: a review of their chemical properties and modifications for therapeutic application. Molecules. 2019;24:4299. [DOI]

36.

Fu Z, Xiang J. Aptamers, the nucleic acid antibodies, in cancer therapy. Int J Mol Sci. 2020;21:2793. [DOI]

37.

Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol. 2009;86:151–64. [DOI]

38.

Sharma VR, Thomas SD, Miller DM, Rezzoug F. Nucleolin overexpression confers increased sensitivity to the anti-nucleolin aptamer, AS1411. Cancer Invest. 2018;36:475–91. [DOI]

39.

Bates PJ, Reyes-Reyes EM, Malik MT, Murphy EM, O’Toole MG, Trent JO. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: uses and mechanisms. Biochim Biophys Acta Gen Subj. 2017;1861:1414–28. [DOI]

40.

Beaver CC, Magnan MA. Managing chemotherapy side effects: achieving reliable and equitable outcomes. Clin J Oncol Nurs. 2016;20:589–91. [DOI] [PubMed]

41.

Hendriks D, Choi G, de Bruyn M, Wiersma VR, Bremer E. Antibody-based cancer therapy: successful agents and novel approaches. Int Rev Cell Mol Biol. 2017;331:289–383. [DOI]

42.

Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394:793–804. [DOI]

43.

Kijanka M, Dorresteijn B, Oliveira S, van Bergen en Henegouwen PM. Nanobody-based cancer therapy of solid tumors. Nanomedicine (Lond). 2015;10:161–74. [DOI] [PubMed]

44.

Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Novel antigens of CAR T cell therapy: new roads; old destination. Transl Oncol. 2021; 14:101079. [DOI] [PubMed]

45.

Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F, Khoshtinat Nikkhoi S. Strategies for dodging the obstacles in CAR T cell therapy. Front Oncol. 2021;11:627549. [DOI] [PubMed] [PMC]

46.

Hashem Boroojerdi M, Rahbarizadeh F, Safarzadeh Kozani P, Kamali E, Safarzadeh Kozani P. Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia. Med Oncol. 2020;37:100. [DOI] [PubMed] [PMC]

47.

Li X, Yu Y, Ji Q, Qiu L. Targeted delivery of anticancer drugs by aptamer AS1411 mediated Pluronic F127/cyclodextrin-linked polymer composite micelles. Nanomedicine. 2015;11:175–84. [DOI]

48.

Chiappetta DA, Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. Eur J Pharm Biopharm. 2007;66:303–17. [DOI]

49.

Chung Y-I, Kim JC, Kim YH, Tae G, Lee SY, Kim K, et al. The effect of surface functionalization of PLGA nanoparticles by heparin-or chitosan-conjugated Pluronic on tumor targeting. J Control Release. 2010;143:374–82. [DOI]

50.

Zhao L, Du J, Duan Y, Zhang H, Yang C, Cao F, et al. Curcumin loaded mixed micelles composed of Pluronic P123 and F68: preparation, optimization and in vitro characterization. Colloids Surf B Biointerfaces. 2012;97:101–8. [DOI]

51.

Qiu LY, Wang RJ, Zheng C, Jin Y, Jin LQ. β-cyclodextrin-centered star-shaped amphiphilic polymers for doxorubicin delivery. Nanomedicine (Lond). 2010;5:193–208. [DOI] [PubMed]

52.

Zhang J, Chen R, Fang X, Chen F, Wang Y, Chen M. Nucleolin targeting AS1411 aptamer modified pH-sensitive micelles for enhanced delivery and antitumor efficacy of paclitaxel. Nano Res. 2015;8:201–18. [DOI]

53.

Zhang R, Wang SB, Wu WG, Kankala RK, Chen AZ, Liu YG, et al. Co-delivery of doxorubicin and AS1411 aptamer by poly(ethylene glycol)-poly(β-amino esters) polymeric micelles for targeted cancer therapy. J Nanopart Res. 2017;19:224. [DOI]

54.

Mohammadzadeh P, Cohan RA, Ghoreishi SM, Bitarafan-Rajabi A, Ardestani MS. AS1411 aptamer-anionic linear globular dendrimer G2-iohexol selective nano-theranostics. Sci Rep. 2017;7:11832. [DOI] [PubMed] [PMC]

55.

Alavidjeh MS, Haririan I, Khorramizadeh MR, Ghane ZZ, Ardestani MS, Namazi H. Anionic linear-globular dendrimers: biocompatible hybrid materials with potential uses in nanomedicine. J Mater Sci Mater Med. 2010;21:1121–33. [DOI]

56.

Assadi A, Najafabadi VS, Shandiz SA, Boroujeni AS, Ashrafi S, Vaziri AZ, et al. Novel chlorambucil-conjugated anionic linear-globular PEG-based second-generation dendrimer: in vitro/in vivo improved anticancer activity. Onco Targets Ther. 2016;9:5531–43. [DOI] [PubMed] [PMC]

57.

Ardestani MS, Fordoei AS, Abdoli A, Ahangari Cohan R, Bahramali G, Sadat SM, et al. Nanosilver based anionic linear globular dendrimer with a special significant antiretroviral activity. J Mater Sci Mater Med. 2015;26:179. [DOI] [PubMed]

58.

Mirzaei M, Mehravi B, Ardestani MS, Ziaee SA, Pourghasem P. In vitro evaluation of Gd(3+)-anionic linear globular dendrimer-monoclonal antibody: potential magnetic resonance imaging contrast agents for prostate cancer cell imaging. Mol Imaging Biol. 2015;17:770–6. [DOI]

59.

Aravind A, Jeyamohan P, Nair R, Veeranarayanan S, Nagaoka Y, Yoshida Y, et al. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng. 2012;109:2920–31. [DOI]

60.

Aravind A, Nair R, Raveendran S, Veeranarayanan S, Nagaoka Y, Fukuda T, et al. Aptamer conjugated paclitaxel and magnetic fluid loaded fluorescently tagged PLGA nanoparticles for targeted cancer therapy. J Magn Magn Mater. 2013;344:116–23. [DOI]

61.

Gao H, Qian J, Cao S, Yang Z, Pang Z, Pan S, et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials. 2012;33:5115–23. [DOI]

62.

Guo J, Gao X, Su L, Xia H, Gu G, Pang Z, et al. Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011;32:8010–20. [DOI]

63.

Lale SV, R G A, Aravind A, Kumar DS, Koul V. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA–PCL–pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy. Biomacromolecules. 2014;15:1737–52. [DOI]

64.

Wu J, Song C, Jiang C, Shen X, Qiao Q, Hu Y. Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery. Mol Pharm. 2013;10:3555–63. [DOI]

65.

Zhou W, Zhou Y, Wu J, Liu Z, Zhao H, Liu J, et al. Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells. J Drug Target. 2014;22:57–66. [DOI]

66.

Zhang B, Luo Z, Liu J, Ding X, Li J, Cai K. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo. J Control Release. 2014;192:192–201. [DOI]

67.

Malik MT, O’Toole MG, Casson LK, Thomas SD, Bardi GT, Reyes-Reyes EM, et al. AS1411-conjugated gold nanospheres and their potential for breast cancer therapy. Oncotarget. 2015;6:22270–81. [DOI] [PubMed] [PMC]

68.

Dam DH, Culver KS, Kandela I, Lee RC, Chandra K, Lee H, et al. Biodistribution and in vivo toxicity of aptamer-loaded gold nanostars. Nanomedicine. 2015;11:671–9. [DOI]

69.

Le Trinh T, Zhu G, Xiao X, Puszyk W, Sefah K, Wu Q, et al. A synthetic aptamer-drug adduct for targeted liver cancer therapy. PLoS One. 2015;10:e0136673. [DOI] [PubMed] [PMC]

70.

Zhang H, Hou L, Jiao X, Ji Y, Zhu X, Li H, et al. In vitro and in vivo evaluation of antitumor drug-loaded aptamer targeted single-walled carbon nanotubes system. Curr Pharm Biotechnol. 2013;14:1105–17. [DOI] [PubMed]

71.

Peng LH, Zhang YH, Han LJ, Zhang CZ, Wu JH, Wang XR, et al. Cell membrane capsules for encapsulation of chemotherapeutic and cancer cell targeting in vivo. ACS Appl Mater Interfaces. 2015;7:18628–37. [DOI] [PubMed]

72.

Kim HJ, Kim YH, Lee DS, Chung JK, Kim S. In vivo imaging of functional targeting of miR-221 in papillary thyroid carcinoma. J Nucl Med. 2008;49:1686–93. [DOI]

73.

Kim HJ, Chung JK, Hwang DW, Lee DS, Kim S. In vivo imaging of miR-221 biogenesis in papillary thyroid carcinoma. Mol Imaging Biol. 2009;11:71–8. [DOI]

74.

Kim JK, Choi KJ, Lee M, Jo MH, Kim S. Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer-and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials. 2012;33:207–17. [DOI]

75.

Coumar MS, Tsai FY, Kanwar JR, Sarvagalla S, Cheung CH. Treat cancers by targeting survivin: just a dream or future reality? Cancer Treat Rev. 2013;39:802–11. [DOI] [PubMed]

76.

Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: patent review. Expert Opin Ther Pat. 2010;20:1723–37. [DOI]

77.

Kanwar JR, Kamalapuram SK, Kanwar RK. Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev. 2013;33:765–89. [DOI]

78.

Sudhakar J, Khetan V, Madhusudan S, Krishnakumar S. Dysregulation of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in advanced retinoblastoma. Br J Ophthalmol. 2014;98:402–7. [DOI]

79.

Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS, et al. Retinoblastoma. Lancet. 2012;379:1436–46. [DOI]

80.

Hinnis A, Luckett J, Walker R. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. B J Cancer. 2007;96:639–45. [DOI]

81.

Du YJ, Li J, Zhu WF, Wu Y, Tang XP, Wang Y, et al. Survivin mRNA-circulating tumor cells predict treatment efficacy of chemotherapy and survival for advanced non-small cell lung cancer patients. Tumor Biol. 2014;35:4499–507. [DOI]

82.

Shehata HH, Abou Ghalia AH, Elsayed EK, Ahmed Said AM, Mahmoud SS. Clinical significance of high levels of survivin and transforming growth factor beta-1 proteins in aqueous humor and serum of retinoblastoma patients. J AAPOS. 2016;20:444.e1–444.e9. [DOI] [PubMed]

83.

Sudhakar J, Venkatesan N, Lakshmanan S, Khetan V, Krishnakumar S, Biswas J. Hypoxic tumor microenvironment in advanced retinoblastoma. Pediatr Blood Cancer. 2013;60:1598–601. [DOI]

84.

Subramanian N, Kanwar JR, Akilandeswari B, Kanwar RK, Khetan V, Krishnakumar S. Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery. Chem Commun (Camb). 2015;51: 6940–3. [DOI]

85.

Liang Z, Wei S, Guan J, Luo Y, Gao J, Zhu H, et al. DNAzyme-mediated cleavage of survivin mRNA and inhibition of the growth of PANC-1 cells. J Gastroenterol Hepatol. 2005;20:1595–602. [DOI]

86.

Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274–84. [DOI] [PubMed]

87.

Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10:760–74. [DOI]

88.

Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non–small-cell lung cancer. N Eng J Med. 2010;363:733–42. [DOI]

89.

Shih JY, Tsai MF, Chang TH, Chang YL, Yuan A, Yu CJ, et al. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res. 2005;11:8070–8. [DOI]

90.

Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25:9–34. [DOI]

91.

Shih JY, Yang PC. The EMT regulator slug and lung carcinogenesis. Carcinogenesis. 2011;32:1299–304. [DOI]

92.

Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415–28. [DOI] [PubMed]

93.

Hong TM, Chen YL, Wu YY, Yuan A, Chao YC, Chung YC, et al. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res. 2007;13:4759–68. [DOI]

94.

Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol. 2009;11:694–704. [DOI]

95.

Kao SH, Wang WL, Chen CY, Chang YL, Wu YY, Wang YT, et al. GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene. 2014;33:3172–82. [DOI]

96.

Lai WY, Wang WY, Chang YC, Chang CJ, Yang PC, Peck K. Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras. Biomaterials. 2014;35:2905–14. [DOI]

97.

Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst. 2001;93:678–83. [DOI]

98.

Kim CJ, Dessureault S, Gabrilovich D, Reintgen DS, Slingluff CL Jr. Immunotherapy for melanoma. Cancer control. 2002;9:22–30. [DOI] [PubMed]

99.

Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19–20. [DOI]

100.

Wagner A, Platzgummer M, Kreismayr G, Quendler H, Stiegler G, Ferko B, et al. GMP production of liposomes--a new industrial approach. J Liposome Res. 2006;16:311–9. [DOI]

101.

Kaneda Y. Virosomes: evolution of the liposome as a targeted drug delivery system. Adv Drug Deliv Rev. 2000;43:197–205. [DOI]

102.

Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, et al. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials. 2014;35:3840–50. [DOI]

103.

Zhao X, Xi Y, Zhang Y, Wu Q, Meng R, Zheng B, et al. Redox-sensitive gelatin/silica-aptamer nanogels for targeted siRNA delivery. Nanoscale Res Lett. 2019;14:273. [DOI] [PubMed] [PMC]

104.

Fan H, Yan G, Zhao Z, Hu X, Zhang W, Liu H, et al. A smart photosensitizer-manganese dioxide nanosystem for enhanced photodynamic therapy by reducing glutathione levels in cancer cells. Angew Chem Int Ed Engl. 2016;55:5477–82. [DOI]

105.

Kong F, Liang Z, Luan D, Liu X, Xu K, Tang B. A glutathione (GSH)-responsive near-infrared (NIR) theranostic prodrug for cancer therapy and imaging. Anal Chem. 2016;88:6450–6. [DOI]

106.

Yu S, Bi X, Yang L, Wu S, Yu Y, Jiang B, et al. Co-delivery of paclitaxel and PLK1-targeted siRNA using aptamer-functionalized cationic liposome for synergistic anti-breast cancer effects in vivo. J Biomed Nanotechnol. 2019;15:1135–48. [DOI]

107.

Li J, Hong MJ, Chow JP, Man WY, Mak JP, Ma HT, et al. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe. Oncotarget. 2015;6:9327–40. [DOI] [PubMed] [PMC]

108.

Gomes-da-Silva LC, Ramalho JS, de Lima MC, Simões S, Moreira JN. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells. Eur J Pharm Biopharm. 2013;85:356–64. [DOI]

109.

King SI, Purdie CA, Bray SE, Quinlan PR, Jordan LB, Thompson AM, et al. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome. Breast Cancer Res. 2012;14:R40. [DOI]

110.

Ha GH, Kim DY, Breuer EK, Kim CK. Combination treatment of polo-like kinase 1 and tankyrase-1 inhibitors enhances anticancer effect in triple-negative breast cancer cells. Anticancer Res. 2018;38:1303–10. [DOI]

111.

Morry J, Ngamcherdtrakul W, Gu S, Reda M, Castro DJ, Sangvanich T, et al. Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform. Mol Cancer Ther. 2017;16:763–72. [DOI]

112.

Kang SH, Cho MJ, Kole R. Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry. 1998;37:6235–9. [DOI]

113.

Kole R, Vacek M, Williams T. Modification of alternative splicing by antisense therapeutics. Oligonucleotides. 2004;14:65–74. [DOI]

114.

Kole R, Williams T, Cohen L. RNA modulation, repair and remodeling by splice switching oligonucleotides. Acta Biochim Pol. 2004;51:373–8. [DOI]

115.

Ming X, Alam MR, Fisher M, Yan Y, Chen X, Juliano RL. Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res. 2010;38:6567–76. [DOI]

116.

Bauman J, Jearawiriyapaisarn N, Kole R. Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides. 2009;19:1–13. [DOI]

117.

Wan J, Sazani P, Kole R. Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells. Int J Cancer. 2009;124:772–7. [DOI]

118.

Zhang N, Peairs JJ, Yang P, Tyrrell J, Roberts J, Kole R, et al. The importance of Bcl-xL in the survival of human RPE cells. Invest Ophthalmol Vis Sci. 2007;48:3846–53. [DOI]

119.

Bauman JA, Li SD, Yang A, Huang L, Kole R. Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res. 2010;38:8348–56. [DOI]

120.

Bauman JA, Kole R. Modulation of RNA splicing as a potential treatment for cancer. Bioeng Bugs. 2011;2:125–8. [DOI] [PubMed] [PMC]

121.

Lundin P, Johansson H, Guterstam P, Holm T, Hansen M, Langel U, et al. Distinct uptake routes of cell-penetrating peptide conjugates. Bioconjug Chem. 2008;19:2535–42. [DOI]

122.

Alam MR, Ming X, Dixit V, Fisher M, Chen X, Juliano RL. The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. Oligonucleotides. 2010;20:103–9. [DOI]

123.

Kotula JW, Pratico ED, Ming X, Nakagawa O, Juliano RL, Sullenger BA. Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Ther. 2012;22:187–95. [DOI]

124.

Tsuda H, Kozu T, Iinuma G, Ohashi Y, Saito Y, Saito D, et al. Cancer prevention by bovine lactoferrin: from animal studies to human trial. Biometals. 2010;23:399–409. [DOI]

125.

Kanwar RK, Kanwar JR. Immunomodulatory lactoferrin in the regulation of apoptosis modulatory proteins in cancer. Protein Pept Lett. 2013;20:450–8. [DOI]

126.

Troost FJ, Steijns J, Saris WH, Brummer RJ. Gastric digestion of bovine lactoferrin in vivo in adults. J Nutr. 2001;131:2101–4. [DOI]

127.

Farnaud S, Evans RW. Lactoferrin--a multifunctional protein with antimicrobial properties. Mol Immunol. 2003;40:395–405. [DOI]

128.

Roy K, Kanwar RK, Kanwar JR. LNA aptamer based multi-modal, Fe3O4-saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging. Biomaterials. 2015;71:84–99. [DOI]

129.

Ai J, Xu Y, Lou B, Li D, Wang E. Multifunctional AS1411-functionalized fluorescent gold nanoparticles for targeted cancer cell imaging and efficient photodynamic therapy. Talanta. 2014;118:54–60. [DOI]

130.

Shieh YA, Yang SJ, Wei MF, Shieh MJ. Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano. 2010;4:1433–42. [DOI] [PubMed]

131.

Rha SY, Izbicka E, Lawrence R, Davidson K, Sun D, Moyer MP, et al. Effect of telomere and telomerase interactive agents on human tumor and normal cell lines. Clin Cancer Res. 2000;6:987–93. [PubMed]

132.

Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3:380–7. [DOI] [PubMed]

133.

Shen Y, Tian Q, Sun Y, Xu JJ, Ye D, Chen HY. ATP-activatable photosensitizer enables dual fluorescence imaging and targeted photodynamic therapy of tumor. Anal Chem. 2017;89:13610–7. [DOI]

134.

Xu L, Wang SB, Xu C, Han D, Ren XH, Zhang XZ, et al. Multifunctional albumin-based delivery system generated by programmed assembly for tumor-targeted multimodal therapy and imaging. ACS Appl Mater Interfaces. 2019;11:38385–94. [DOI]

135.

Fan X, Sun L, Wu Y, Zhang L, Yang Z. Bioactivity of 2’-deoxyinosine-incorporated aptamer AS1411. Sci Rep. 2016;6:25799. [DOI]

136.

Lee KY, Kang H, Ryu SH, Lee DS, Lee JH, Kim S. Bioimaging of nucleolin aptamer-containing 5-(N-benzylcarboxyamide)-2’-deoxyuridine more capable of specific binding to targets in cancer cells. J Biomed Biotechnol. 2010;2010:168306. [DOI]

137.

Hwang DW, Ko HY, Lee JH, Kang H, Ryu SH, Song IC, et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med. 2010;51:98–105. [DOI]

138.

Noaparast Z, Hosseinimehr SJ, Piramoon M, Abedi SM. Tumor targeting with a 99mTc-labeled AS1411 aptamer in prostate tumor cells. J Drug Target. 2015;23:497–505. [DOI]

139.

Maremanda NG, Roy K, Kanwar RK, Shyamsundar V, Ramshankar V, Krishnamurthy A, et al. Quick chip assay using locked nucleic acid modified epithelial cell adhesion molecule and nucleolin aptamers for the capture of circulating tumor cells. Biomicrofluidics. 2015;9:054110. [DOI]